CYTOKINETICS INC

(c) In this Item 5(c) of this quarterly report on Form 10-Q, the terms “officers”, “rule 10b5-1 trading arrangements” and “non-Rule 10b5-1 trading arrangements” have the meanings ascribed to them in Item 408 of Regulation S-K.

The following directors and officers adopted into or terminated a Rule 10b5-1 trading arrangement during the second quarter of 2025:

•

Robert A. Harrington, M.D. – Dr. Harrington adopted a Rule 10b5-1 trading arrangement on May 9, 2025 that was intended to satisfy the affirmative defense provided for under Rule 10b5-1(c) (the “Harrington Plan”). The Harrington Plan provides for the sale of up to 4,300 shares of our common stock at pre-specified dates during the term of the plan. The Harrington Plan will terminate on the earlier of (x) December 5, 2025 and (y) the sale of all securities that are subject to the plan.

•

Wendell Wierenga, Ph.D. – Dr. Wierenga adopted a Rule 10b5-1 trading arrangement on May 14, 2025 that was intended to satisfy the affirmative defense provided for under Rule 10b5-1(c) (the “Wierenga Plan”). The Wierenga Plan provides for the exercise of stock options to acquire up to 28,407 shares of our common stock and the concurrent sale of all shares of common stock acquired upon such exercise during the term of the plan. The Wierenga Plan will terminate on the earlier of (x)January 1, 2027 and (y) the sale of all securities that are subject to the plan.

Certain of our officers have made elections to participate in, and are participating in, our employee stock purchase plan, which may be designed to satisfy the affirmative defense conditions of Rule 10b5-1 under the Exchange Act or may constitute non-Rule 10b5–1 trading arrangements. In addition, certain of our directors have made elections to participate in, and are participating in, our director equity in lieu of cash retainer option program (as described in the “Director Compensation” section of our Proxy Statement for our 2024 Annual Meeting), which may be designed to satisfy the affirmative defense conditions of Rule 10b5-1 under the Exchange Act or may constitute non-Rule 10b5–1 trading arrangements.